ReviewInternational journal of molecular sciences2026
Toll-like Receptor 3 as a Context-Dependent Molecular Switch in Epithelial Cancers: Balancing Cell Death and Tumor-Supportive Programs.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Toll-like receptor 3 (TLR3) is a double-stranded RNA sensor that plays a dual and context-dependent role in epithelial cancers, promoting either regulated cell death (RCD) or tumor-supportive programs. While TLR3 activation has been widely explored for its capacity to induce apoptosis or necroptosis and enhance antitumor immunity, accumulating evidence indicates that cancer cells can use TLR3 signaling to sustain proliferation, migration, stemness, and therapy resistance. In this review, we provide a comprehensive and mechanistic analysis of TLR3 signaling in epithelial cancers, encompassing canonical and non-canonical modules that regulate cancer cell fate. We examine how TLR3 activation engages interconnected RCD programs, including apoptosis, necroptosis, and immunogenic cell death, and contrast these with pathways driving tumor plasticity and progression. Importantly, we discuss the key determinants governing TLR3 signaling output, including signaling complex composition; ligand origin and delivery; TLR3 subcellular localization; and cancer cell-intrinsic factors such as genetic, epigenetic, and metabolic states. We propose an integrative framework in which TLR3 signaling influences cancer cell fate according to cellular and microenvironmental context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.